Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies

Core Insights - Cognition Therapeutics, Inc. is advancing its investigational drug zervimesine (CT1812) for treating dementia with Lewy bodies (DLB) and has conducted a Type C meeting with the FDA to discuss the Phase 2b study [1][2] Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related neurodegenerative disorders [4] - The company has completed Phase 2 studies for zervimesine in DLB and mild-to-moderate Alzheimer's disease, with ongoing studies supported by an $81 million grant from the National Institute of Aging [4] Drug Development - Zervimesine is an oral, once-daily pill aimed at treating CNS diseases, specifically targeting the toxic effects of Aβ and ɑ-synuclein proteins that contribute to neurodegeneration [2] - The drug has shown promise in interrupting the toxic effects of these proteins, potentially slowing disease progression and improving patient quality of life [2] Regulatory Engagement - The FDA meeting was described as productive, focusing on clinically meaningful endpoints for the upcoming Phase 2b study [2] - The company anticipates receiving meeting minutes from the FDA later this quarter, indicating ongoing communication to advance clinical development [2]